Group 1 - Institutional investors bought a total of 30 stocks, with net purchases in 9 stocks and net sales in 21 stocks on the day [1] - The top three stocks with the highest institutional purchases were: Limin Co., Ltd. (¥193 million), Anglikang (¥170 million over three days), and Aoyang Health (¥13.56 million) [1] - Limin Co., Ltd. saw a net purchase of ¥193 million from 5 institutions, benefiting from rising prices of key products such as Abamectin and Mancozeb, which is expected to enhance its profitability [3] Group 2 - The stock of Limin Co., Ltd. increased by 10.02% with 3 buyers and 2 sellers [2] - Anglikang's stock rose by 9.98% with 4 buyers and 2 sellers [2] - The automotive industry is experiencing a shift as major companies have committed to standardizing supplier payment terms to 60 days, which may alleviate profit pressures across the industry [3]

Group 1 - The stock of Anglikon (002940) reached the daily limit, with a trading volume of 1.393 billion yuan and a turnover rate of 29.07% [1] - Institutional trading data shows that four specialized institutional seats had a net purchase of 235 million yuan, while two specialized institutional seats had a net sale of 65.137 million yuan [1] - There is a notable influx of dark pool funds into certain stocks, indicating potential investment interest [1]

10日，A股、港股午后全线回落，创业板指、科创50指数等跌超1%，恒生科技指数跌近1%。 具体来看，两市股指早盘窄幅震荡，午后加速下探。截至收盘，沪指跌0.44%报3384.82点，深证成指跌0.86% 报10162.18点，创业板指跌1.17%报2037.27点，科创50指数跌1.47%，北证50指数跌约1%，沪深北三市合计成 交14516亿元，较此前一日增加近1400亿元。 场内超4000股飘绿，半导体、军工、石油、券商、酿酒等板块走低；银行板块走强，民生银行一度涨约4%， 兴业银行、南京银行盘中创出新高；农业板块拉升，种业股表现亮眼，秋乐种业、康农种业涨超10%；离境退 税概念崛起，国航远洋30%涨停，宁波海运、南京港、连云港等涨停；创新药概念再度活跃，昂利康连续3日 涨停，一品红、泰恩康涨超9%均创出新高；稀土概念持续强势，中科磁业、科恒股份等涨停；短剧概念尾盘 异动，中文在线涨超13%，慈文传媒涨停；体育概念热度不减，共创草坪斩获7连板。 离境退税概念盘中大幅走高，截至收盘，国航远洋30%涨停，华光源海涨近27%，宁波远洋、南京港、连云港 等均涨停。 | 代码 | 名称 | 4 | 涨幅% | 现价 ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ A股三大股指6月10日开盘涨跌互现。早盘指数分化，沪指在银行股走强下表现较强。午后两市快速下 挫，沪指更是一度跌1%。 从盘面上看，TMT行业全线调整，半导体、算力、AI应用、金融科技、消费电子概念股跌幅靠前。离 境退税、稀土永磁、种业题材午后逆势上涨；新消费、创新药概念股活跃。 至收盘，上证综指跌0.44%，报3384.82点；科创50指数跌1.47%，报982.9点；深证成指跌0.86%，报 10162.18点；创业板指跌1.17%，报2037.27点。 Wind统计显示，两市及北交所共1260只股票上涨，4034只股票下跌，平盘有118只股票。 沪深两市成交总额14153亿元，较前一交易日的12864亿元增加1289亿元。其中，沪市成交5574亿元，比 上一交易日5119亿元增加455亿元，深市成交8579亿元。 两市及北交所共有79只股票涨幅在9%以上，10只股票跌幅在9%以上。 计算机板块领跌两市，退市龙宇（维权）（603003）跌超30%，新致软件（688590）、中科信息 （300678）、慧博云通（301316）、石基信 ...

Group 1 - The innovative drug concept is gaining strength, with stocks like Anglikang and others hitting the daily limit up [1] - Anglikang has achieved a remarkable performance of 4 limit-ups in 6 days [1] - Other companies such as Zhongsheng Pharmaceutical and Hasanlian also reached the daily limit up, while Ruizhi Pharmaceutical and Saiseng Pharmaceutical increased by over 10% [1] Group 2 - The State Council has issued opinions aimed at improving basic medical insurance drug catalog adjustment mechanisms [1] - The new policies are designed to better meet the multi-level medication guarantee needs of the public [1]

Group 1 - The stock of Zhejiang Anglikang Pharmaceutical Co., Ltd. experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 20% over two consecutive trading days (June 6 and June 9, 2025) [1] - The company's board confirmed that there are no undisclosed significant matters that could impact the stock price, and previous disclosures do not require correction or supplementation [2][3] - The company is currently conducting a clinical trial for its innovative drug project ALK-N001, which received approval in April 2025 and is in the I phase of clinical trials [1][3] Group 2 - The company has verified that its operational status remains normal, with no significant changes in its main business or external operating environment [1] - The board has not identified any undisclosed information that should be disclosed according to the Shenzhen Stock Exchange regulations [2] - The company emphasizes the long development cycle and high investment required for innovative drug research, highlighting the inherent uncertainties and risks involved [3]

Group 1 - Company Gongchuang Turf (605099.SH) stated that the impact of domestic football events on its operations and performance is minimal, as its main business of artificial turf has a low revenue contribution from domestic sports grass [1] - Company Anglikang (002940.SZ) confirmed that its innovative drug project ALK-N001 is still in Phase I clinical trials, indicating a long R&D cycle and significant investment [2] - Company Yiwei Lithium Energy (300014.SZ) plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance capital strength and international brand image [3] Group 2 - Company Chaohongji (002345.SZ) also intends to issue H-shares and apply for listing on the Hong Kong Stock Exchange to advance its global strategy and improve competitiveness [4] - Company Dexin Technology (603032.SH) clarified that its subsidiary's sales revenue from products used in solid-state battery production is less than 1% of total revenue, emphasizing its focus on quality service [5] - Company Changshan Pharmaceutical (300255.SZ) announced that its application for the marketing authorization of Aibennapeptide injection for type 2 diabetes has been accepted, but the approval timeline remains uncertain [6] Group 3 - Company Baili Electric (600468.SH) reported that its revenue from nuclear fusion-related business is currently minimal, accounting for less than 1% of total revenue [7] - Company Chutianlong (003040.SZ) is exploring digital currency projects but faces risks related to new technology development and commercial application [8] - Company Dongxing Medical (301290.SZ) signed contracts with Shanghai Jiao Tong University for synthetic biology technology development, totaling 6 million yuan, enhancing its R&D capabilities [9] Group 4 - Company Maixinlin (688685.SH) announced that its subsidiary signed contracts for computing power services worth 1.184 billion yuan, expected to positively impact future performance [10] - Company Haichen Pharmaceutical (300584.SZ) reported that its solid-state battery-related business has not yet generated revenue, which does not significantly affect overall performance [11] - Company Filinger (603226.SH) is undergoing stock trading suspension for investigation due to significant price deviations from fundamentals [12] Group 5 - Company Zhongdian Port (001287.SZ) disclosed that the National Integrated Circuit Fund reduced its stake by 1%, now holding 8.97% of the company [13] - Company Huasheng Co., Ltd. (600156.SH) is planning to acquire 100% of Yixin Technology, leading to a stock suspension for up to 10 trading days [14] - Company Jianghuai Automobile reported a 3.52% year-on-year decline in May sales, with new energy vehicle sales down 57.81% [15] - Company Aonong Biological reported a 9.44% year-on-year increase in May pig sales, with a total of 156,200 pigs sold [16]

Group 1 - The stock of Zhejiang Anglikang Pharmaceutical Co., Ltd. (stock code: 002940) experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 20% over two consecutive trading days (June 6, 2025, and June 9, 2025) [1] - The company's board of directors conducted an investigation into the abnormal trading situation and confirmed that there were no undisclosed significant information or major changes affecting the company [1][2] - The only ongoing project is ALK-N001, which received clinical trial approval in April 2025 and is currently in Phase I clinical trials, highlighting the long cycle, high investment, and uncertainty associated with innovative drug development [1][2] Group 2 - The board confirmed that there are no undisclosed matters that should be disclosed according to the Shenzhen Stock Exchange listing rules, nor any significant information that could impact the stock price [2] - The company emphasizes the importance of rational decision-making for investors, given the inherent risks in the long and costly drug development process [2]

浙江昂利康制药股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 证券代码：002940 证券简称：昂利康 公告编号：2025-043 浙江昂利康制药股份有限公司（以下简称"公司"或"本公司"）股票（证 券代码：002940，证券简称：昂利康）连续 2 个交易日（2025 年 6 月 6 日、2025 年 6 月 9 日）收盘价格涨幅偏离值累计超过 20%，根据《深圳证券交易所交易规 则》的相关规定，属于股票交易异常波动的情况。 二、公司关注并核实的相关情况 针对公司股票交易异常波动情况，公司董事会对有关事项进行了核查，有关 情况说明如下： 1、公司前期披露的信息不存在需要更正或补充披露的事项； 2、公司未发现近期公共传媒报道了可能或已经对公司股票交易价格产生较 大影响的未公开重大信息； 3、经核查，公司目前经营情况正常，主营业务未发生变化，内外部经营环 境未发生重大变化； 4、经核查，公司及控股股东、实际控制人不存在关于本公司的应披露而未 披露的重大事项，也不存在处于筹划阶段的重大事项； 一、股票交易异常波动的情况介绍 三、是 ...

Core Viewpoint - The company, Angli Kang (002940.SZ), has experienced significant stock price fluctuations, with a cumulative deviation of over 20% in closing prices over two consecutive trading days, attributed to abnormal trading activity [1] Company Summary - The company confirmed that there are no corrections or supplementary disclosures needed for previously released information, and there have been no significant changes in the internal or external operating environment [1] - The company and its controlling shareholders have not engaged in any stock trading during the period of abnormal price fluctuations [1] - The innovative drug project ALK-N001 is currently in Phase I clinical trials, characterized by a long research and development cycle and substantial investment requirements, indicating potential investment risks for investors [1]